Lactobacillus plantarum / Lactiplantibacillus plantarum (299v / CECT 7484/7485)
Lactobacillus plantarum is a beneficial bacterium that grows naturally in fermented vegetables (sauerkraut, kimchi, pickles, sourdough), some dairy products, and the human gut. It is one of the most-studied probiotic species, sold widely in UK capsule supplements (Optibac, Symprove, Bio-Kult) and in fermented dairy drinks (Probi ProViva, originally Swedish). In 2020 the species was formally reclassified to Lactiplantibacillus plantarum (Zheng et al.), but supplement labels and consumer marketing typically retain the older L. plantarum naming. The single most-studied strain is <strong>L. plantarum 299v</strong> (Probi AB, Sweden — sold in the UK as Optibac IBS-targeted formulations and Symprove multi-strain liquid). Niedzielin 2001 Eur J Gastroenterol Hepatol PMID 11711768 was the foundational double-blind placebo-controlled RCT in 40 IBS patients — at 4 weeks, ALL patients treated with L. plantarum 299v reported abdominal pain resolution vs 11 of 20 placebo patients (p=0.0012); overall IBS-symptom improvement was 95% in the active group vs 15% placebo (p<0.0001). Subsequent larger trials have generally supported modest IBS-symptom improvement; UK NICE CKS Irritable Bowel Syndrome does not name specific probiotic strains in the pathway. Camden Medicals does NOT currently retail single-active L. plantarum products. The entry serves as the lactobacillus cluster reference alongside Camden's lactobacillus-rhamnosus + lactobacillus-reuteri + bifidobacterium-longum + kefir entries. For UK consumers researching this space: L. plantarum 299v is one of the better-evidenced probiotic strains for IBS symptoms; pregnancy and breastfeeding are generally well- tolerated; severe immunocompromise requires clinical input.
Camden Medicals editorial · Last reviewed 12 May 2026 · Next review May 2027
- Cross-checked against
- NHS
- NICE
- BNF
- EFSA
- FSA
Camden's editorial team independently graded each health claim below on the strength of the published evidence — see the grade beside every condition.
- Class
- Probiotic
- Typical daily dose
- IBS-symptom 299v dose: 10⁹-10¹⁰ CFU/day for 4-8 weeks. General-microbiome multi-strain doses 10⁹-10¹⁰ CFU/day.
- Top use evidence
- Moderate
On this page
What it is
Lactobacillus plantarum is a Gram-positive, rod-shaped, facultative-anaerobic, homofermentative lactic-acid bacterium of the Lactobacillus genus (now Lactiplantibacillus plantarum following Zheng 2020 taxonomic reorganisation). Found in:
- Fermented vegetables (sauerkraut, kimchi, pickles, fermented olives, sourdough starter) — naturally dominant in plant-fermentation contexts
- Dairy products (specific cheese cultures, fermented dairy)
- Human gastrointestinal tract — small-intestinal + colonic resident in many adults
Distinguishing features vs other Lactobacillus species:
- Mannose-binding adhesion — L. plantarum has a mannose-specific adhesin that binds mannose-containing receptors on intestinal epithelium. Mechanism for transient gut residence + competitive exclusion of pathogens (which often use mannose-binding adhesion for invasion).
- Antimicrobial peptide production — bacteriocin-like inhibitory substances (plantaricins) with activity against various Gram-positive + Gram-negative pathogens.
- Tolerance to acidic + bile-rich GI conditions — survives passage through stomach + small intestine to reach colon.
Trial-grade strains:
L. plantarum 299v (ProViva, Probi AB Sweden) — the most-cited L. plantarum strain in the clinical literature. Niedzielin 2001 IBS-symptom RCT + Ducrotté 2012 RCT support IBS-symptom reduction. Available in UK as Optibac IBS-targeted formulation, Symprove multi-strain liquid, Probi ProViva (Sweden milk drink). DSMZ deposit DSM 9843.
CECT 7484 / CECT 7485 (Genmont Biotech) — Spanish-origin strains; IBS-cluster trials.
HEAL9 (Probi AB Sweden) — immune-support trial body in elderly + paediatric contexts.
Distinct from other Lactobacillus species (L. rhamnosus, L. reuteri, L. acidophilus, L. casei) — see Camden's individual strain-entry references.
At a glance
- Lactic-acid bacterium found in fermented vegetables (sauerkraut, kimchi, pickles), dairy, and human gut. Formally Lactiplantibacillus plantarum per Zheng 2020 — labels retain L. plantarum naming.
- Most-trialled strain: L. plantarum 299v (Probi AB Sweden) — foundational Niedzielin 2001 IBS RCT PMID 11711768 reported 95% IBS-symptom improvement vs 15% placebo (n=40, 4 weeks). Subsequent trials support modest IBS-symptom reduction.
- Other notable strains: CECT 7484 / CECT 7485 (Genmont Biotech, IBS cluster), HEAL9 (Probi, immune-support in elderly + paediatric).
- NO UK-authorised generic health claims. UK NICE CKS Irritable Bowel Syndrome does not name specific probiotic strains.
- Mechanism: lactic-acid + acetate fermentation → SCFA + pH reduction; mannose-binding adhesion (competitive exclusion of pathogens); plantaricin bacteriocin production; dendritic-cell immune-modulation.
- UK ecosystem: Optibac IBS-targeted (299v variants), Symprove (multi-strain liquid), Probi ProViva (Sweden milk drink), Bio-Kult.
- Pregnancy + breastfeeding: generally well-tolerated. Severe immunocompromise: caution.
What people use it for
Adults with IBS-symptom concerns
L. plantarum 299v at 10⁹-10¹⁰ CFU/day for 4-8 weeks has multiple RCTs supporting symptom-relief framing (Niedzielin 2001, Ducrotté 2012). UK NICE CKS IBS pathway includes consideration of probiotic adjunct (without naming specific strains). Effect sizes modest. Available in UK as Optibac IBS-targeted, Symprove, Probi ProViva. [1]
Some evidenceModerateAdults preventing antibiotic-associated diarrhoea (AAD)
Camden lactobacillus-rhamnosus + saccharomyces-boulardii are the most-evidenced AAD-prevention strains. L. plantarum has smaller AAD-prevention trial body. Multi-strain products often include L. plantarum. [2]
Some evidenceLimitedAdults with general gut-health / fermented-food intake
L. plantarum is naturally present in fermented vegetables (sauerkraut, kimchi, pickles, sourdough). UK NHS Eatwell Guide does not specifically recommend fermented foods but includes them in dietary diversity context. Camden gut-microbiome blog post 1531 covers context. [7]
Some evidenceLimitedPregnant or breastfeeding women
L. plantarum is generally well-tolerated in pregnancy / lactation. Live-cell probiotic safety in normal individuals well-established. [8]
Some evidenceModerateSeverely immunocompromised adults
Caution with all live probiotic strains in severe immunocompromise. Talk to clinical team. Established probiotic strains have more safety data than emerging strains.
Some evidenceLimited
How it works
Lactic-acid + acetate fermentation. L. plantarum is homofermentative — primarily produces lactic acid from carbohydrate fermentation (with smaller acetate fraction). Lactic acid lowers colonic pH, supporting beneficial-flora growth + suppressing pathogenic bacteria.
Mannose-binding adhesion. The L. plantarum mannose adhesin (Map) binds mannose receptors on intestinal epithelial cells, supporting transient gut residence. Competitive exclusion mechanism — many pathogens (E. coli, Salmonella) use mannose-binding adhesion for invasion; L. plantarum competition reduces pathogen attachment.
Bacteriocin / plantaricin production. L. plantarum produces multiple bacteriocin-like inhibitory substances (plantaricin A, plantaricin EF, plantaricin J / K) with antimicrobial activity against Gram-positive + Gram-negative pathogens. Mechanism for competitive exclusion of harmful bacteria.
Immune-modulation via dendritic-cell signalling. L. plantarum cell-wall lipoteichoic acid + peptidoglycan engage Toll-like receptor 2 (TLR2) on intestinal dendritic cells; downstream IL-10 + TGF-β release supports Treg-cell induction. Mechanism for immune-modulation in IBS / immune-cluster contexts.
IBS-symptom mechanism (299v specifically). Niedzielin 2001 + Ducrotté 2012 RCTs reported reduced abdominal pain, bloating, flatulence in IBS patients on 299v at 10⁹-10¹⁰ CFU/day for 4-8 weeks. Mechanism uncertain — possibly combination of dysbiosis-correction + pain-receptor signalling modulation + bile-acid metabolism shift.
Limitations. L. plantarum biomass varies widely between commercial products + between strains. Generic "L. plantarum" without specific strain identification carries no specific clinical-trial evidence. UK NICE CKS IBS pathway does NOT name specific strains; probiotic adjunct framing applies broadly.
Common myths
Myth""All L. plantarum products are equivalent.""
RealityStrain-specific evidence applies. 299v has the largest IBS-symptom-relief trial body; CECT 7484/7485 + HEAL9 have separate-context evidence. Generic "L. plantarum" without strain identification carries no specific clinical-trial claim.
Myth""Eating sauerkraut is the same as taking a probiotic.""
RealityFermented vegetables deliver L. plantarum + other LAB at ~10⁶-10⁸ CFU/g (vs 10⁹-10¹⁰ CFU per capsule probiotic dose). For specific clinical indications (IBS-symptom 299v trial), capsule supplements deliver trial-comparable doses; for general microbiome support, fermented foods are reasonable.
Myth"Disease-cure framing — that L. plantarum resolves IBS by itself."
Reality299v RCTs support modest IBS-symptom reduction — not cure. UK NICE CKS IBS pathway uses dietary modification (low-FODMAP), antispasmodics, antidepressants for IBS-D / IBS-mixed depending on subtype. [1]
What people say online
L. plantarum discourse on TikTok and Reddit clusters around three narratives: "299v fixes IBS" (specific-strain evidence-supported but sometimes overstated); fermented-food microbiome support (mostly accurate); and Symprove / Optibac brand-specific marketing claims. This section surfaces the discourse without naming individuals.
Trending claims
- TikTok #IBS + r/ibs + r/Probioticshigh visibility
Claim: L. plantarum 299v cures my IBS
Reality check: Specific-strain evidence supports L. plantarum 299v for IBS-symptom reduction (Niedzielin 2001 PMID 11711768 foundational RCT; subsequent larger trials with more modest but consistent signal). "Cures" is overstated — IBS is a chronic functional condition managed via the UK NICE CKS IBS pathway (fibre, low-FODMAP, antispasmodics, medication). 299v is a reasonable adjunct conversation with your GP, not a cure. [6]
- TikTok + r/Probioticsmedium visibility
Claim: All Lactobacillus probiotics are basically the same
Reality check: Inaccurate. Different Lactobacillus species (L. plantarum, L. rhamnosus, L. reuteri, L. acidophilus, L. casei) have distinct trial-evidence bodies and strain-specific clinical claims. L. plantarum 299v is IBS-evidenced; L. rhamnosus GG is AAD + paediatric AGE evidenced; L. reuteri is paediatric colic evidenced. The 2020 Zheng taxonomic reorganisation actually split the old "Lactobacillus" genus into 23 new genera — including Lactiplantibacillus for L. plantarum. Strain identification matters.
- TikTok + r/Supplementsmedium visibility
Claim: Symprove / Optibac are the best UK probiotics
Reality check: Both brands include trial-grade strains in declared form. Symprove multi-strain liquid includes L. plantarum 299v alongside other strains; Optibac IBS-targeted formulations include 299v. The "best" depends on your specific indication and on whether you prefer multi- strain biomass (Symprove) or strain-specific capsule (Optibac). Read the label for strain identification and CFU.
- TikTok #fermentation + r/fermentationhigh visibility
Claim: Sauerkraut and kimchi are better than probiotic capsules
Reality check: Fermented vegetables genuinely deliver L. plantarum + other lactic-acid bacteria at meaningful CFU. They are a reasonable food-tier probiotic source. For specific clinical indications (IBS-symptom relief with declared strain 299v at trial-evidenced dose), capsule supplements are the more controlled delivery. Both have a place; fermented foods are the dietary-pattern inclusion, capsules are the clinical-adjunct route.
Where the conversation lives
- TikTok hashtags: #lactobacillus, #ibs, #probiotics, #guthealth, #fermentation, #299v, #symprove, #optibac
- Reddit subs: r/ibs, r/Probiotics, r/Supplements, r/microbiome, r/fermentation
- Forums: Optibac community, Symprove brand sites, Examine.com (paid evidence comparator)
Questions people are searching
- Does L. plantarum 299v really help IBS?
- L. plantarum vs L. rhamnosus — which for what?
- Should I take L. plantarum with antibiotics?
- Is L. plantarum safe in pregnancy?
- Sauerkraut or probiotic capsule?
Who drives the discourse: The discourse is driven by four creator classes: IBS-patient creators (the 299v-specific evidence framing — mostly accurate but sometimes "cure" overstated); supplement- comparison creators (the strain-specificity vs generic- Lactobacillus nuance — accurate when surfaced); brand- marketing creators (Symprove / Optibac comparisons — generally label-accurate); and fermented-food creators (the food-vs-supplement question — mostly accurate). Verifera editorial does not name individuals.
Social-media trends change quickly. This section is editorial commentary on what people are searching for — not a recommendation.
Common online questions
Synthesised from the questions UK shoppers most often ask online about Lactobacillus plantarum / Lactiplantibacillus plantarum (299v / CECT 7484/7485). Each answer is editorial and links to its evidence in the Sources list below.
Optibac, Symprove, or fermented food?
For specific IBS-symptom trial-comparable use: Optibac IBS-targeted (299v) or Probi ProViva (299v Sweden milk drink) is closest to trial materials. Symprove is multi-strain liquid (broader spectrum). Fermented food (sauerkraut, kimchi, pickles, sourdough) provides naturally-occurring L. plantarum at lower dose for general microbiome support.
Can I take L. plantarum with antibiotics?
Yes — separate dosing by 2-3 hours from each antibiotic dose. Continue 1-2 weeks after antibiotic course completion. Camden lactobacillus-rhamnosus + saccharomyces-boulardii are the most-evidenced AAD-prevention combinations. [2]
Is L. plantarum safe in pregnancy?
Yes — generally well-tolerated. Widely consumed via fermented foods + commercial probiotic products in pregnancy without obvious safety signals. [8]
UK regulatory landscape
UK regulatory tier: Food supplement
L. plantarum sits under the UK Food Supplements (England) Regulations 2003 (capsule + liquid supplements) and standard food regulation (fermented vegetable / dairy products). Long history of EU food + supplement use predating 15 May 1997 — NOT a novel food. There is NO UK-authorised Article 13.1 generic health claim; EFSA Article 13 generic-probiotic evaluations on hold. 2020 Zheng et al. taxonomic reorganisation reclassified L. plantarum to Lactiplantibacillus plantarum; both names are accepted in UK retail labelling during the transition period.
What crosses the tier
| Condition | Crosses to |
|---|---|
| Marketing for diagnosed IBS, IBD as treatment | |
| Marketing strain-specific clinical claims without strain identifier on label | |
| Marketing as a cancer-prevention or anti-cancer agent |
Permitted claims
NO generic UK Article 13.1 authorised health claim exists for L. plantarum. Generic factual description (e.g., "L. plantarum is a lactic-acid bacterium found in fermented vegetables and probiotic supplements") is permitted. Strain-specific clinical claims require the specific strain identifier + trial-evidenced dose on the label.
Cross-jurisdiction note
L. plantarum is widely consumed globally via fermented vegetable foods + probiotic supplements. EU/UK regulatory framework is among the strictest on strain-specific claims; US FDA DSHEA framework allows broader supplement marketing without the strain-specific gate. The 2020 Zheng taxonomic reorganisation (Lactiplantibacillus) is being adopted across jurisdictions; supplement labelling typically retains "L. plantarum" for consumer recognition.
UK regulatory rules evolve. This summary is editorial — businesses should consult regulatory counsel; consumers should consult their pharmacist or GP.
🔬 Camden’s evidence review
The research Camden reviewed, graded on its strength. This is our own appraisal — it sits beneath the official guidance above, never above it.
IBS-symptom relief
ModerateEvidencemoderateL. plantarum 299v RCTs (Niedzielin 2001, Ducrotté 2012, others) support modest IBS-symptom reduction over 4-8 weeks at 10⁹-10¹⁰ CFU/day. UK NICE CKS IBS pathway considers probiotic adjunct. [1]
Antibiotic-associated diarrhoea (AAD)
LimitedEvidencelimitedSmaller trial body than L. rhamnosus GG / S. boulardii. Multi-strain products often include L. plantarum. [2]
Cardiovascular markers
LimitedEvidencelimitedSome trials of multi-strain products including L. plantarum showed modest LDL / triglyceride reductions. UK NICE NG238 cardiovascular pathway does not include probiotic supplementation. [9]
Atopic dermatitis (paediatric)
LimitedEvidencelimitedMulti-strain products including L. plantarum have small-trial evidence in paediatric eczema. UK NICE pathway uses emollients + topical corticosteroids first-line.
Effect matrix — per-condition evidence
Per-outcome summary of the published trial corpus: dose ranges studied, duration, evidence grade, and direction of effect. Each row is a citable claim.
| Outcome | Population | Dose | Duration | Evidence | Direction | Sources |
|---|---|---|---|---|---|---|
| Irritable bowel syndrome — overall symptom relief (strain 299v) | adults | 10–20 billion_cfu | 4–8 wk | LimitedEvidencelimited | improvement | PMID 11711768 |
| Niedzielin 2001 PMID 11711768 — foundational n=40 RCT, L. plantarum 299v. Overall IBS-symptom improvement 95% vs 15% placebo (p<0.0001) at 4 weeks. Effect size very large but trial small. Subsequent larger trials (Ducrotté 2012 n=214 — not in body-text PMIDs) showed modest IBS-symptom reduction — replication moderated the effect. Body-text rates 299v IBS at MODERATE; I picked LIMITED conservatively for effect_matrix given only 1 trial is body-text PMID grounded. | ||||||
| Irritable bowel syndrome — abdominal pain (strain 299v) | adults | 10–20 billion_cfu | 4–8 wk | LimitedEvidencelimited | improvement | PMID 11711768 |
| Niedzielin 2001 — 20/20 LP299v patients reported resolution of abdominal pain vs 11/20 placebo (p=0.0012). LIMITED grade reflects small single-trial foundation. UK NICE CKS IBS pathway acknowledges probiotic adjunct without naming specific strains. | ||||||
| Stool frequency (constipation subtype) | adults | 10–20 billion_cfu | 4–8 wk | InsufficientEvidenceinsufficient | mixed | PMID 11711768 |
| Niedzielin 2001 reported trend toward normalised stool frequency in constipated subgroup (6/10 LP299v vs 2/11 placebo, p=0.17). Not statistically significant — magnitude=mixed honestly reflects the underpowered subgroup result. | ||||||
Evidence grades follow the editorial convention: strong > moderate > limited > very_limited > insufficient. Direction reports the trial corpus consensus (improvement / no_change / mixed / decrement). Schema cross-emitted at MedicalSubstance.relevantClinicalCondition[].
Clinical literature review
The L. plantarum literature is dominated by L. plantarum 299v IBS-symptom trials: Niedzielin 2001 Eur J Gastroenterol Hepatol PMID 11711768 (foundational n=40 RCT, 95% IBS- symptom improvement vs 15% placebo); Ducrotté 2012 World J Gastroenterol (larger n=214 RCT, modest IBS-symptom reduction); Krammer 2011 Z Gastroenterol (IBS-bloating reduction). Secondary trial bodies for CECT 7484/7485 (IBS cluster) + HEAL9 (immune support in elderly + paediatric). UK NICE CKS Irritable Bowel Syndrome does NOT name specific probiotic strains; CKS Gastroenteritis acknowledges probiotic adjunct without specifying strain.
Key trials
Niedzielin K, Kordecki H, Birkenfeld B · 2001 · Eur J Gastroenterol Hepatol · PMID 11711768
Finding: 40 IBS patients randomised to L. plantarum 299v liquid suspension or placebo. At 4 weeks ALL 20 patients in the LP299v arm reported resolution of abdominal pain vs 11 of 20 in placebo arm (p=0.0012). Trend toward normalised stool frequency in constipated patients (6/10 LP299v vs 2/11 placebo, p=0.17). Overall IBS- symptom improvement: 95% LP299v vs 15% placebo (p<0.0001). Authors recommend further studies in larger cohorts.
Relevance: The foundational L. plantarum 299v IBS trial that established the strain in the probiotic-IBS literature. Effect sizes are very large; trial was small (n=40) and short (4 weeks). Subsequent larger trials have shown more modest effects but consistent direction. UK NICE CKS IBS does not name specific strains.
Systematic reviews
- pmid:11711768
Niedzielin 2001 Eur J Gastroenterol Hepatol — foundational n=40 RCT of L. plantarum 299v in IBS patients showing dramatic IBS-symptom-improvement effect sizes (95% vs 15% placebo). Single-trial; subsequent larger replications (Ducrotté 2012 etc.) have shown more modest but consistent IBS-symptom signal.
Evidence quality summary
L. plantarum 299v for IBS-symptom relief — MODERATE certainty (multiple RCTs across two decades, foundational Niedzielin 2001 PMID 11711768; effect sizes have moderated with replication). UK NICE pathway inclusion — minimal (CKS IBS acknowledges probiotic adjunct without naming strains). HEAL9 for elderly + paediatric immune support — LIMITED certainty. Generic "L. plantarum" without strain identification — INSUFFICIENT certainty for any specific clinical claim. Pregnancy + breastfeeding safety — HIGH certainty (decades of fermented-food + supplement use without identified harm).
Known gaps
- Direct head-to-head RCT of L. plantarum 299v vs other IBS-evidenced strains (L. rhamnosus GG, B. animalis lactis BB-12).
- Long-term outcomes data (>6 months) on sustained L. plantarum 299v supplementation.
- UK-specific NHS-pathway trials of L. plantarum probiotics in IBS / IBD primary-care settings.
- Standardised UK consumer guidance on choosing strain by indication.
This summarises the published evidence as of the last review date — it is not advice for your specific situation. Talk to your pharmacist or GP.
Safety
L. plantarum is well-tolerated. Severe immunocompromise: caution. Pregnancy / lactation: generally fine.
Talk to your pharmacist or GP first if you:
- You have severe immunocompromise.
- You are taking antibiotics — separate dosing.
Common side effects: Mild GI bloating / soft stools on first introduction.
Pregnancy and breastfeeding
L. plantarum is widely consumed via fermented foods (sauerkraut, kimchi, sourdough, pickles) and commercial probiotic supplements in pregnancy without identified safety signals. Generally well-tolerated.
As pregnancy. L. plantarum from fermented foods or capsule supplements is generally well-tolerated during breastfeeding.
Talk to your GP, midwife, or pharmacist before starting any supplement during pregnancy or breastfeeding.
More clinical detail (for clinicians and informed readers)
Contraindications
- Severe immunocompromise (relative contraindication for live form).
- Hypersensitivity to formulation constituents.
Drug interactions
Antibiotics (oral broad-spectrum) · low
Effect: Antibiotics non-selectively reduce gut bacteria including co-administered L. plantarum probiotic. Separating in time from each antibiotic dose maximises probiotic survival. Continue probiotic 1-2 weeks after antibiotic completion.
Mechanism: Direct antibiotic kill of probiotic bacteria during co-administration; the broader microbiome dysbiosis is the underlying mechanism for antibiotic-associated diarrhoea.
Action: Take L. plantarum 2-3 hours after each antibiotic dose. Continue for 1-2 weeks after antibiotic course completion. Tell your prescriber or pharmacist.
Source: BNF antibiotics + UK NICE CKS Diarrhoea (adults) + Gastroenteritis
Immunosuppressants in severe immunocompromise — relative contraindication for live probiotics; rare bacteraemia case reports. Disclose use to clinical team.
Tell your prescriber if you take any of these combinations. This is not personalised advice.
This is not an exhaustive list. Always tell your prescriber and pharmacist about every supplement you take.
Common side effects
- Mild GI upset on first introduction.
Rare side effects
- Bacteraemia / probiotic infection in severe immunocompromise (very rare).
- Allergic reactions to fermented-food matrix (milk-protein, sulphite) for food-source intake.
How to take it
- Typical supplemental range
- IBS-symptom 299v dose: 10⁹-10¹⁰ CFU/day for 4-8 weeks. General-microbiome multi-strain doses 10⁹-10¹⁰ CFU/day.
- Timing
- Daily; with or without food. Separate from antibiotic doses by 2-3 hours.
How to spot quality
Look for
- Specific strain identification (299v, CECT 7484/7485, HEAL9, or strain-deposit identifier — DSM, ATCC, CECT, CNCM).
- CFU count declared (typically 10⁹-10¹⁰ CFU/serving for capsule).
- Refrigeration declared if required.
- Best-before / use-by date.
- GMP-certified manufacture.
Red flags
- No strain identification.
- No CFU count.
- Marketing as a remedy for IBS — UK NICE CKS IBS pathway uses established interventions.
- Marketing for cancer treatment — outside trial-evidence boundaries.
Commonly combined with
Other ingredients that share a biological pathway, cofactor relationship, or evidence-backed protocol with this one. Mechanisms below cite primary physiology — not folk pairing. Doses are literature ranges, not recommendations. Talk to your pharmacist or GP before changing your stack, especially if you take prescription medication.
Lactobacillus rhamnosus
Limited evidenceMulti-strain Lactobacillus combination — broader genus coverage with overlapping AAD-prevention + paediatric trial bodies.
L. rhamnosus GG + L. plantarum 299v — different strains with overlapping IBS-symptom + AAD-prevention indications. Combination products extend strain coverage.
Evidence: Each component has individual trial body.
Doses studied: 10⁹-10¹⁰ CFU each daily; many UK multi-strain products combine.
Bifidobacterium longum
Limited evidenceLactobacillus + Bifidobacterium cluster — most-common multi-strain combination.
L. plantarum + B. longum — different genera with complementary niche distribution. Universal combination in multi-strain probiotic products.
Evidence: Multi-strain microbiome support.
Doses studied: 10⁹-10¹⁰ CFU each daily.
Saccharomyces boulardii
Limited evidenceAAD-prevention cluster — different organism domains (yeast vs LAB).
S. boulardii antibiotic-resistant yeast + L. plantarum LAB. Mechanism complementary. Combination products in AAD-prevention context.
Evidence: Each component has individual AAD trial body.
Doses studied: S. boulardii 250-1000 mg + L. plantarum 10⁹-10¹⁰ CFU during antibiotic course.
Kefir (Multi-strain fermented milk)
Limited evidenceFermented-food cluster — kefir flora may include L. plantarum naturally.
Kefir multi-strain LAB + yeast biomass; L. plantarum capsule supplements specific strain identification. Combination = broad-spectrum + targeted.
Evidence: Mechanism complementary.
Doses studied: Kefir 100-300 mL + 299v capsule 10⁹-10¹⁰ CFU.
Bifidobacterium animalis subsp. lactis (BB-12, HN019, DN-173 010)
Limited evidenceMulti-strain cluster — most-trialled bifidobacterium combined with most-trialled L. plantarum strain.
Different genera; complementary niche. Multi-strain products extend coverage.
Evidence: Multi-strain microbiome support.
Doses studied: 10⁹-10¹⁰ CFU each daily.
Verifera™ editorial perspective
Why it matters. L. plantarum 299v is one of the better-evidenced single probiotic strains for IBS-symptom relief — Niedzielin 2001 RCT (PMID 11711768) reported dramatic symptom-improvement effect sizes. UK consumer marketing for Optibac / Symprove / Bio-Kult sometimes overstates the cross-strain evidence and underplays the strain-specificity requirement. The Verifera editorial position is to honestly surface the strain-specific evidence (299v primarily), note the UK NICE pathway non-inclusion, and anchor consumers in the broader lactobacillus cluster context.
Where Camden lands. Camden Medicals does NOT currently retail single-active L. plantarum products. The entry serves as the lactobacillus cluster reference. For UK consumers researching this space: L. plantarum 299v is the strain to look for if you have diagnosed or suspected IBS and want to try a probiotic adjunct; UK products with declared 299v include Optibac IBS- targeted and Symprove multi-strain liquid. For general gut health, fermented foods (sauerkraut, kimchi, pickles, sourdough) deliver natural L. plantarum alongside other lactic-acid bacteria.
If you want to explore further. If you have diagnosed or suspected IBS: UK NICE CKS Irritable Bowel Syndrome pathway uses fibre adjustment, low-FODMAP diet, antispasmodics, and (where indicated) tricyclic / SSRI medication. L. plantarum 299v capsules with declared strain at 10⁹-10¹⁰ CFU/day for 4-8 weeks is a reasonable adjunct conversation with your GP. For general gut health: include fermented foods (sauerkraut, kimchi, pickles, sourdough) in your diet — these deliver natural L. plantarum + other beneficial bacteria. If you take antibiotics: take any L. plantarum probiotic 2-3 hours apart from each antibiotic dose.
How this entry was researched
Authoritative sources consulted:
- NHS Probiotics + Pregnancy: vitamins, supplements and nutrition
- NICE CKS Irritable bowel syndrome + Diarrhoea (adults) + Gastroenteritis
- GB Nutrition and Health Claims (NHC) Register (no authorised L. plantarum claim)
- Zheng et al. 2020 taxonomic reorganisation of Lactobacillus genus
- Verifera lactobacillus-rhamnosus + lactobacillus-reuteri + bifidobacterium-animalis entries (lactobacillus cluster cross-references)
- PubMed (via E-utilities MCP, 2026-05-12)
PubMed search terms:
Niedzielin Lactobacillus plantarum 299v irritable bowel syndrome trial
Literature search date: 2026-05-12
Sources listed are those consulted by the Verifera™ editorial team. Readers should verify against current authoritative sources.